TY - JOUR
T1 - A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum
T2 - An umbrella review of systematic reviews and meta-analyses
AU - Groening, Johanna Manja
AU - Denton, Emma
AU - Parvaiz, Rimsha
AU - Brunet, David Losada
AU - Von Daniken, Aisha
AU - Shi, Yiling
AU - Bhattacharyya, Sagnik
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2024/1
Y1 - 2024/1
N2 - While the legal status and public perception of cannabis are currently changing in many countries, one of the important considerations from a public health viewpoint is its potential association with adverse health outcomes such as the development of psychosis. We conducted an umbrella review of systematic reviews and meta-analyses using the AMSTAR-2 to assess the quality of included reviews. We further created an evidence map to visualize and facilitate the overview of the published evidence synthesis on the association between cannabis use and all psychosis-related outcomes and risk moderators in healthy, high-risk, and clinical populations. Overall, we found 32 systematic reviews and meta-analyses. Based on a synthesis of current evidence, cannabis use is associated with subclinical psychosis states (psychotic-like experiences) and traits (schizotypal personality) in the healthy population, as well as earlier onset and development of psychosis. An association with the clinical-high-risk state for psychosis, attenuated psychosis symptoms and transition to psychosis in this population could not be confirmed. An association between cannabis use and psychosis outcomes in patients with psychotic disorder could solely be confirmed regarding relapse. Whether causal effects underlie those associations has not sufficiently been addressed in the evidence synthesis to date.
AB - While the legal status and public perception of cannabis are currently changing in many countries, one of the important considerations from a public health viewpoint is its potential association with adverse health outcomes such as the development of psychosis. We conducted an umbrella review of systematic reviews and meta-analyses using the AMSTAR-2 to assess the quality of included reviews. We further created an evidence map to visualize and facilitate the overview of the published evidence synthesis on the association between cannabis use and all psychosis-related outcomes and risk moderators in healthy, high-risk, and clinical populations. Overall, we found 32 systematic reviews and meta-analyses. Based on a synthesis of current evidence, cannabis use is associated with subclinical psychosis states (psychotic-like experiences) and traits (schizotypal personality) in the healthy population, as well as earlier onset and development of psychosis. An association with the clinical-high-risk state for psychosis, attenuated psychosis symptoms and transition to psychosis in this population could not be confirmed. An association between cannabis use and psychosis outcomes in patients with psychotic disorder could solely be confirmed regarding relapse. Whether causal effects underlie those associations has not sufficiently been addressed in the evidence synthesis to date.
KW - Clinical high-risk for psychosis
KW - Marijuana
KW - Psychotic disorders
KW - Psychotic-like-experiences
KW - Relapse
KW - Schizophrenia
KW - Schizotypy
UR - http://www.scopus.com/inward/record.url?scp=85180509872&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2023.115626
DO - 10.1016/j.psychres.2023.115626
M3 - Review article
C2 - 38096722
AN - SCOPUS:85180509872
SN - 0165-1781
VL - 331
JO - Psychiatry Research
JF - Psychiatry Research
M1 - 115626
ER -
